par Bruntsch, Uta;Dodion, Pierre ;ten Bokkel Huinink, Wim;Hansen, Heine;Pinedo, Herbert H.M.;Hansen, Mogens;Renard, Josette;van Glabbeke, Martine
Référence European journal of cancer & clinical oncology, 22, 6, page (697-699)
Publication Publié, 1986-06
Référence European journal of cancer & clinical oncology, 22, 6, page (697-699)
Publication Publié, 1986-06
Article révisé par les pairs
Résumé : | Fourteen patients with metastatic renal adenocarcinoma without prior chemotherapy were treated with 1,2,4-triglycidylurazol (TGU, NSC-332488), a new triepoxide alkylating agent. TGU was chosen for this study among other triepoxides because of its high antitumour activity in animal models, its relatively good water solubility and the expected favourable therapeutic index. The starting dose was 800 mg/m2 i.v. (600 mg/m2 for patients with prior extensive radiotherapy) every 4 weeks. No objective tumour regression was seen in this favourable group of patients. Leuko- and thrombocytopenia were the most important side-effects. Severe cumulative and prolonged thrombocytopenia was seen. Other toxicities observed were nausea with or without vomiting in all patients and local phlebitis in some. © 1986. |